Status:
COMPLETED
Cognitive Behavioral Therapy (CBT) Study Evaluating the Updating of Persecutory Beliefs
Lead Sponsor:
Vanderbilt University Medical Center
Conditions:
Schizophrenia; Psychosis
Persecutory Delusion
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The purpose of this study is to examine how Bayesian belief updating changes throughout psychotherapeutic treatment for persecutory delusions. Specifically, individuals with a psychotic disorder diagn...
Eligibility Criteria
Inclusion
- Men and women age 18 - 65.
- Communicative in English.
- Premorbid Intelligence \>79 (WTAR)
- Provide voluntary, written informed consent.
- Physically healthy by medical history.
- Weight \<300 lbs
- Stable medication regimen over at least the past two weeks, including the use of either an oral or intramuscular administration of an antipsychotic medication.
- Diagnosis of a non-affective psychotic disorder (schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, brief psychotic disorder, psychosis NOS) confirmed by Structured Clinical Interview for Diagnostic and Statistical Manual (DSM)-5 (SCID) or diagnostic interview with a trained clinician.
- A persecutory delusion scoring at least a 3 on the conviction scale of the Psychotic Symptoms Rating Scale (PSYRATS) that had persisted for at least two weeks and that was not considered the direct result of substance use
- A clinically significant level of worry, as shown by a score of at least 44 on the Penn State Worry Questionnaire (PSWQ).
Exclusion
- Age less than 18 or greater than 65.
- Not communicative in English.
- Premorbid IQ \< 79 (WTAR)
- Unable to provide written informed consent.
- Current medical or neurological illness.
- History of severe head trauma.
- Weight \>300 lbs
- Primary diagnosis of alcohol or substance use disorder or personality disorder
- Conditions that preclude fMRI scanning (as defined in the fMRI Screening Form)
- Subjects who are actively involved with individual cognitive therapy (Past experience with individual therapy is not an exclusion)
Key Trial Info
Start Date :
March 30 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 29 2024
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT04748679
Start Date
March 30 2021
End Date
May 29 2024
Last Update
August 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37212